Financings In Brief: Guilford Pharmaceuticals
Executive Summary
Guilford Pharmaceuticals: Baltimore-based neurological diseases R&D firm closes offering of 3 mil. shares of common stock, resulting in estimated net proceeds of $18 mil. Guilford notes Aug. 16 that it sold most of the shares to institutional investors at $6.50 per share. Guilford originally intended to offer 1.8 mil. shares but increased the offering in response to greater demand. Oppenheimer & Co. was the placement agent for the offering. Guilford will use the proceeds to complete the commercialization of its Gliadel implant for brain cancer and for earlier-stage products for brain cancer and nerve degeneration...
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth